Market Cap 4.16B
Revenue (ttm) 107.94M
Net Income (ttm) -107.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -99.45%
Debt to Equity Ratio 0.00
Volume 713,500
Avg Vol 887,112
Day's Range N/A - N/A
Shares Out 57.82M
Stochastic %K 43%
Beta 0.34
Analysts Strong Sell
Price Target $114.81

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 5:42 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.50 - $4.60 Sell Price: $7.31 Profit : +109% (Turn every $1 into $2.09) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:14 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $72.58, significantly below its 60-day high of $94.07, indicating potential for recovery. The RSI of 29.64 suggests the stock is in oversold territory, which may lead to a rebound. The moving averages (MA30 at 81.36 and MA50 at 83.36) indicate a bearish trend, but the proximity to the 60D low of $66.00 provides a support level. Directional Bias: The oversold RSI indicates a potential bullish reversal, while the trading range suggests room for upward movement. Trade Plan: - Suggested Entry: $72.58 - Stop Loss: $66.00 (below the 60D low) - Take Profit Targets: 1. $78.00 (Target 1, 7.5% ROI) 2. $83.00 (Target 2, 14.3% ROI) 3. $85.00 (Target 3, 17.1% ROI) This plan provides a clear path for potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 2:51 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.50 - $4.00 Sell Price: $5.92 Profit : +69% (Turn every $1 into $1.69) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 12:32 PM
$ACLX Current Stock Price: $70.84 Contracts to trade: $70 ACLX Dec 19 2025 Call Entry: $3.15 Exit: $4.39 ROI: 39% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:17 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $70.84, significantly below its 60-day high of $94.07, indicating potential for a rebound. The RSI at 26.31 suggests the stock is oversold, creating a bullish bias. Directional Bias: The stock is currently underperforming, as indicated by its position below both the 30-day (82.33) and 50-day (83.75) moving averages. However, the low RSI and proximity to the 60-day low of $66.00 suggest a reversal opportunity. Trade Plan: - Suggested Entry: $71.00 (slightly above the last close to confirm upward momentum) - Stop Loss: $66.00 (below the 60-day low to limit risk) - Take Profit Targets: 1. $78.00 (10% gain) 2. $83.00 (16% gain) 3. $83.00 (17% gain) This plan offers a potential ROI of over 17% on the third target, capitalizing on the oversold conditions and potential for a price recovery. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
topstockalerts
topstockalerts Dec. 9 at 8:55 PM
Early-phase cancer trial results boosted several small biotech stocks. Terns Pharmaceuticals reported that its leukemia drug TERN-701 reduced cancer cell counts by over 99% in nearly 75% of patients, sending shares up as much as 50%. The pill outperformed Novartis’ Scemblix in efficacy, convenience, and side effects. Analysts see a large market potential, with Terns stock valued up to $58. Arcellx saw shares rise 13% after its multiple-myeloma CAR-T therapy showed comparable efficacy to Legend Biotech’s Carvykti but with fewer side effects. CAR-T treatment modifies a patient’s T-cells to target cancer cells, showing strong results even in heavily pre-treated patients. Legend Biotech shares fell over 10% due to competition, while Johnson & Johnson also experienced a minor dip. Analysts expect Arcellx’s therapy to file for marketing approval next year. $TERN $NOVN $ACLX $LEGN $JNJ
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 9 at 1:38 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $5.10 Sell Price: $9.12 Profit : +112% (Turn every $1 into $2.12) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:16 PM
@CarlosLacombe $ACLX Arcellx reported iMMagine-1 Phase 2 data showing 96% ORR and 74% CR/sCR, with no delayed neurotoxicity. The company reiterated plans for a 2026 launch.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:06 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX closed at $76.65, currently showing bearish momentum with an RSI of 32.93, indicating oversold conditions. The stock is trading below its 30-day (MA30) and 50-day (MA50) moving averages, which are at $82.94 and $83.96 respectively. The recent price action is near the 60-day low of $66.00, suggesting potential for a rebound. Directional Bias: Given the oversold RSI and proximity to the 60-day low, a bullish reversal is anticipated. The stock has room to rally towards its moving averages. Trade Plan: - Suggested Entry: $76.65 (last close) - Stop Loss: $66.00 (60-day low) - Take Profit Targets: 1. $82.00 (MA30) – 7% ROI 2. $86.00 (near MA50) – 12% ROI 3. $90.00 (60D High) – 17% ROI This trade plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 8 at 8:43 PM
Dufus here, $ACLX has soared 3% higher to 6% (~3Mv) in the last few minutes, 12/19 options, follow for more volatility.
0 · Reply
Latest News on ACLX
Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 4 days ago

Cancer Study Buoys These Small Biotechs

LEGN TERN


Why Is Arcellx Stock Surging Today?

Dec 8, 2025, 1:23 PM EST - 5 days ago

Why Is Arcellx Stock Surging Today?


Arcellx Provides Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 5 weeks ago

Arcellx Provides Third Quarter 2025 Financial Results


Arcellx (ACLX) Q2 Revenue Drops 72%

Aug 7, 2025, 4:53 PM EDT - 4 months ago

Arcellx (ACLX) Q2 Revenue Drops 72%


Arcellx Impressive Safety Data Leaves Doubts

Mar 17, 2025, 11:27 AM EDT - 9 months ago

Arcellx Impressive Safety Data Leaves Doubts


Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results


Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences


Arcellx: Navigating The CAR T-Cell Revolution

Jan 30, 2024, 5:13 AM EST - 2 years ago

Arcellx: Navigating The CAR T-Cell Revolution


Kite and Arcellx Announce Expansion in Strategic Partnership

Nov 15, 2023, 6:00 AM EST - 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD


ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Nov 15, 2023, 6:00 AM EST - 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD


Arcellx Provides First Quarter Financial Results

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results


MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 5:42 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.50 - $4.60 Sell Price: $7.31 Profit : +109% (Turn every $1 into $2.09) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:14 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $72.58, significantly below its 60-day high of $94.07, indicating potential for recovery. The RSI of 29.64 suggests the stock is in oversold territory, which may lead to a rebound. The moving averages (MA30 at 81.36 and MA50 at 83.36) indicate a bearish trend, but the proximity to the 60D low of $66.00 provides a support level. Directional Bias: The oversold RSI indicates a potential bullish reversal, while the trading range suggests room for upward movement. Trade Plan: - Suggested Entry: $72.58 - Stop Loss: $66.00 (below the 60D low) - Take Profit Targets: 1. $78.00 (Target 1, 7.5% ROI) 2. $83.00 (Target 2, 14.3% ROI) 3. $85.00 (Target 3, 17.1% ROI) This plan provides a clear path for potential gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 2:51 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.50 - $4.00 Sell Price: $5.92 Profit : +69% (Turn every $1 into $1.69) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 12:32 PM
$ACLX Current Stock Price: $70.84 Contracts to trade: $70 ACLX Dec 19 2025 Call Entry: $3.15 Exit: $4.39 ROI: 39% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:17 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $70.84, significantly below its 60-day high of $94.07, indicating potential for a rebound. The RSI at 26.31 suggests the stock is oversold, creating a bullish bias. Directional Bias: The stock is currently underperforming, as indicated by its position below both the 30-day (82.33) and 50-day (83.75) moving averages. However, the low RSI and proximity to the 60-day low of $66.00 suggest a reversal opportunity. Trade Plan: - Suggested Entry: $71.00 (slightly above the last close to confirm upward momentum) - Stop Loss: $66.00 (below the 60-day low to limit risk) - Take Profit Targets: 1. $78.00 (10% gain) 2. $83.00 (16% gain) 3. $83.00 (17% gain) This plan offers a potential ROI of over 17% on the third target, capitalizing on the oversold conditions and potential for a price recovery. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
topstockalerts
topstockalerts Dec. 9 at 8:55 PM
Early-phase cancer trial results boosted several small biotech stocks. Terns Pharmaceuticals reported that its leukemia drug TERN-701 reduced cancer cell counts by over 99% in nearly 75% of patients, sending shares up as much as 50%. The pill outperformed Novartis’ Scemblix in efficacy, convenience, and side effects. Analysts see a large market potential, with Terns stock valued up to $58. Arcellx saw shares rise 13% after its multiple-myeloma CAR-T therapy showed comparable efficacy to Legend Biotech’s Carvykti but with fewer side effects. CAR-T treatment modifies a patient’s T-cells to target cancer cells, showing strong results even in heavily pre-treated patients. Legend Biotech shares fell over 10% due to competition, while Johnson & Johnson also experienced a minor dip. Analysts expect Arcellx’s therapy to file for marketing approval next year. $TERN $NOVN $ACLX $LEGN $JNJ
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 9 at 1:38 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $5.10 Sell Price: $9.12 Profit : +112% (Turn every $1 into $2.12) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 9 at 1:16 PM
@CarlosLacombe $ACLX Arcellx reported iMMagine-1 Phase 2 data showing 96% ORR and 74% CR/sCR, with no delayed neurotoxicity. The company reiterated plans for a 2026 launch.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:06 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX closed at $76.65, currently showing bearish momentum with an RSI of 32.93, indicating oversold conditions. The stock is trading below its 30-day (MA30) and 50-day (MA50) moving averages, which are at $82.94 and $83.96 respectively. The recent price action is near the 60-day low of $66.00, suggesting potential for a rebound. Directional Bias: Given the oversold RSI and proximity to the 60-day low, a bullish reversal is anticipated. The stock has room to rally towards its moving averages. Trade Plan: - Suggested Entry: $76.65 (last close) - Stop Loss: $66.00 (60-day low) - Take Profit Targets: 1. $82.00 (MA30) – 7% ROI 2. $86.00 (near MA50) – 12% ROI 3. $90.00 (60D High) – 17% ROI This trade plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 8 at 8:43 PM
Dufus here, $ACLX has soared 3% higher to 6% (~3Mv) in the last few minutes, 12/19 options, follow for more volatility.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 5:50 PM
Canaccord Genuity has updated their rating for Arcellx ( $ACLX ) to Buy with a price target of 130.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:37 PM
Needham has updated their rating for Arcellx ( $ACLX ) to Buy with a price target of 105.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 8 at 1:35 PM
$ACLX (+13.1% pre) Arcellx reports positive trial data for multiple myeloma treatment - SI https://ooc.bz/l/86593
0 · Reply
notreload_ai
notreload_ai Dec. 8 at 12:03 PM
$ACLX gets strong support as Morgan Stanley, BofA, and Needham all reiterate Buy ratings with price targets around $105$112.
0 · Reply
notreload_ai
notreload_ai Dec. 8 at 11:49 AM
New data confirms $ACLX anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses. https://notreload.xyz/anito-cel-deep-durable-rrmm-response-no-neurotoxicity/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 10:02 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.80 - $4.30 Sell Price: $8.86 Profit : +106% (Turn every $1 into $2.06) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
justiceforb_85
justiceforb_85 Dec. 7 at 2:46 AM
$ACLX data on anito-cel is pretty good though there may be concern for TAM and the stock has been relentlessly selling off.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:05 AM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $68.45, significantly below its 60-day high of $94.07, indicating potential for upward movement. The RSI at 22.75 suggests the stock is oversold, indicating a possible reversal. Directional Bias: The stock is currently in a downtrend as indicated by the MA30 (83.7) and MA50 (84.2) being above the current price. However, the extreme RSI suggests a potential bounce back. The price is also near the 60-day low of $66.0, providing a strong support level. Trade Plan: - Suggested Entry: $68.50 - Stop Loss: $66.00 (risking $2.50) - Take Profit Targets: 1. Target 1: $75.00 (10% ROI) 2. Target 2: $80.00 (16.5% ROI) 3. Target 3: $80.00 (17% ROI) With the potential for a strong rebound, this trade offers a solid risk-reward ratio. Monitor closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 6 at 2:01 AM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $3.80 - $4.30 Sell Price: $8.94 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:40 PM
Actionable Trade Alert for $ACLX: Market Context: $ACLX is currently trading at $68.45, significantly below its 60-day high of $94.07, indicating potential for upward movement. The RSI at 22.75 suggests the stock is oversold, indicating a possible reversal. Directional Bias: The stock is currently in a downtrend as indicated by the MA30 (83.7) and MA50 (84.2) being above the current price. However, the extreme RSI suggests a potential bounce back. The price is also near the 60-day low of $66.0, providing a strong support level. Trade Plan: - Suggested Entry: $68.50 - Stop Loss: $66.00 (risking $2.50) - Take Profit Targets: 1. Target 1: $75.00 (10% ROI) 2. Target 2: $80.00 (16.5% ROI) 3. Target 3: $80.00 (17% ROI) With the potential for a strong rebound, this trade offers a solid risk-reward ratio. Monitor closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
options1315
options1315 Dec. 4 at 7:55 PM
$ACLX I absolutely NAILED this SHORT.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 6:11 PM
Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $4.90 Sell Price: $6.45 Profit : +50% (Turn every $1 into $1.50) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply